Een fase 1 AAV-gentherapieonderzoek ter evaluatie van veiligheid en voorlopige werkzaamheid van RP-A701 bij personen met Bag3 verwijde cardiomyopathie
A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human BCL2-associated Athanogene 3 (BAG3) Gene Coding Sequence (RP-A701) in Subjects With Dilated Cardiomyopathy Arising From Pathogenic BAG3 Variants (BAG3-DCM)
This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Clinical Information
- Telefoonnummer: 646-627-0033
- E-mail: clinicaltrials@rocketpharma.com
Studie Locaties
-
-
California
-
San Diego, California, Verenigde Staten, 92037
- Werving
- University of California, San Diego
-
Hoofdonderzoeker:
- Barry Greenberg, MD
-
Contact:
- Clinical Research Coordinator
- Telefoonnummer: 858-822-1722
- E-mail: emoyacespedes@health.ucsd.edu
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic
-
Hoofdonderzoeker:
- John Giudicessi, MD, PhD
-
Contact:
- Clinical Research Coordinator
- Telefoonnummer: 507-538-1500
- E-mail: slade.sierra@mayo.edu
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina
-
Hoofdonderzoeker:
- Daniel Judge, MD
-
Contact:
- Clinical Res
- Telefoonnummer: 843-792-2300
- E-mail: andrewcl@musc.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Subjects are eligible for inclusion into the study only if all the following criteria apply:
-
Male or female between 18 and 65 years of age at the time of signing the informed consent
-
Capable of and willing to provide signed informed consent
-
Clinical diagnosis of DCM defined as and requiring each of the following:
- Mild to moderate systolic dysfunction (LVEF ≥ 25% and ≤ 45%) by echocardiography or CMR performed within 3 months of enrollment.
- Absence of severe coronary artery disease (>70% stenosis) or active myocardial ischemia as the etiology of LV systolic dysfunction
- Absence of uncontrolled hypertension, significant cardiac valve disease (i.e., greater than moderate in severity), infiltrative disorder, or systemic disease known to cause cardiomyopathy.
-
Documentation of a pathogenic or likely pathogenic variant in BAG3
-
History of ICD implantation ≥ 3 months prior to enrollment
-
NYHA Class II or III HF symptoms with stable HF therapeutic guideline-directed medical regimen for 30 days prior to enrollment
Exclusion Criteria:
- CV disease that may be related to a genetic etiology other than a BAG3 pathogenic or likely pathogenic variant.
- Previous participation in a study of gene transfer or gene editing.
- I.V. inotropic, vasodilator, or diuretic therapy ≤ 30 days prior to enrollment.
- History of intracardiac thrombosis or arterial thromboembolic events
- Severe RV dysfunction assessed by echocardiogram or CMR ≤ 12 months prior to screening
- LVEF < 25% by echocardiogram or CMR at ≤ 3 months prior to screening
- NYHA Class I or IV HF
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Single ascending dose of RP-A701 in up to 2 consecutive cohorts
Participants will receive a single intravenous dose of RP-A701 on Day 0 and will be followed for up to two years |
One-time treatment with a single ascending dose |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Treatment-emergent Adverse Events (TEAE)
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Number of participants with Adverse Events following a single IV dose of RP-A701 |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
Incidence of Treatment-emergent Serious Adverse Events (SAE).
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Number of participants with Serious Adverse Events (SAE) following a single IV dose of RP-A701 |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
Incidence of Dose Limiting Toxicities (DLT).
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Number of participants with Dose Limiting Toxicities (DLT) following a single IV dose of RP-A701 |
Baseline up to End of Study (up to 24 months post-infusion)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To assess the impact of RP-A701 on features of cardiovascular function.
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in measures of LV systolic function, including LV ejection fraction (LVEF), LV global longitudinal strain. |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the impact of RP-A701 on features of cardiovascular function.
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in peak oxygen consumption (VO2) or ventilatory efficiency (VE/VCO2 slope) by cardiopulmonary exercise test (CPET) |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the impact of RP-A701 on features of cardiovascular function.
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in 6-minute walk distance. |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the extent of RP-A701 transduction and protein expression.
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in BAG3 myocardial protein expression |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the impact of RP-A701 on features of heart failure (HF).
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in symptoms of HF assessed by New York Heart Association (NYHA) class. |
Baseline up to End of Study (up to 24 months post-infusion)
|
|
To assess the impact of RP-A701 on quality of life.
Tijdsspanne: Baseline up to End of Study (up to 24 months post-infusion)
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ-12) Overall Summary Score. |
Baseline up to End of Study (up to 24 months post-infusion)
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Laminopathieën
- Pathologische aandoeningen, anatomisch
- Genetische ziekten, aangeboren
- Cardiomegalie
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Pathologische aandoeningen, tekenen en symptomen
- Hartfalen
- Hart-en vaatziekten
- Hartziekten
- Cardiomyopathieën
- Cardiomyopathie, verwijd
- Dilatatie, pathologisch
Andere studie-ID-nummers
- RP-A701-0125
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .